Insmed Incorporated (INSM)
$16.75
Rating:
Recommendation:
Buy
Symbol | INSM |
---|---|
Price | $16.75 |
Beta | 1.567 |
Volume Avg. | 1.32M |
Market Cap | 2.285B |
Shares () | - |
52 Week Range | 16.04-28.94 |
1y Target Est | - |
DCF Unlevered | INSM DCF -> | |
---|---|---|
DCF Levered | INSM LDCF -> | |
ROE | -867.19% | Strong Sell |
ROA | -29.07% | Sell |
Operating Margin | - | |
Debt / Equity | 1783.36% | Strong Buy |
P/E | -4.23 | Strong Sell |
P/B | 23.43 | Strong Buy |
Latest INSM news
About
Download (Excel)Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.